Replies to post #43387 on Biotech Values

[ThomasS]

MATK: agreed.
>they appear a tad fully-valued for what they do, i.e., not a full-fledged biotech, per se.<

I was implying that their deserved multiple is somewhat less than a pure-play bio like DNA/GENZ yet more than a homebuilder. Your analogy to a weak-pipelined pharma seems appropriate.